Paper Details

  1. Home
  2. Paper Details

Clinical Utility of Pharmacogenomic Data Collected by a Health-System Biobank to Predict and Prevent Adverse Drug Events.

Author: AlobaidlyMaryam, AmatoMary G, BatesDavid W, GammalRoseann S, HasanSarah, KrierJoel B, ReyesDariel Delos, SegerDiane L, ShahSonam N

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Patients with actionable pharmacogenomics (PGx) results who received relevant medications experienced predictable adverse drug events (ADEs).
Paper Details　
Original Abstract of the Article :
INTRODUCTION: Medication-related harm represents a significant issue for patient safety and quality of care. One strategy to avoid preventable adverse drug events is to utilize patient-specific factors such as pharmacogenomics (PGx) to individualize therapy. OBJECTIVE: We measured the number of pat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s40264-021-01050-6

データ提供：米国国立医学図書館（NLM）

Harnessing Pharmacogenomics for Personalized Medicine

Medication-related harm is a significant concern in healthcare, and this study explores the potential of pharmacogenomics (PGx) to improve patient safety. The researchers investigated the clinical utility of PGx data collected through a health-system biobank, specifically focusing on four genes with known drug interactions. Their analysis involved identifying patients with actionable PGx results, examining their medication histories, and assessing the incidence of potential adverse drug events (ADEs).

The Power of PGx Data for Personalized Therapy

The study found a significant correlation between patients' PGx profiles and the occurrence of predictable ADEs. The researchers observed that patients carrying specific variants in the HLA-A*31:01, HLA-B*15:02, TPMT, and VKORC1 genes were more likely to experience ADEs when prescribed interacting medications. This demonstrates the potential of PGx testing to personalize therapy and minimize drug-related complications.

The Future of Personalized Healthcare

This research represents a significant step towards a future of personalized healthcare. It highlights the value of integrating PGx data into electronic health records, enabling clinicians to make informed prescribing decisions based on individual genetic profiles. The study underscores the potential of PGx to enhance patient safety and optimize therapeutic outcomes.

Dr. Camel's Conclusion

This research is like a caravan of scientists traversing the desert of genetic information, uncovering the personalized medicine potential of PGx. The findings demonstrate the importance of tailoring treatment plans based on individual genetic profiles, enhancing patient safety and optimizing therapeutic outcomes. Just as camels adapt to the diverse desert landscape, personalized medicine allows us to adapt our healthcare approaches to the unique needs of each individual.

Date :
  1. Date Completed 2022-04-20
  2. Date Revised 2022-04-20
Further Info :

Pubmed ID

33620701

DOI: Digital Object Identifier

10.1007/s40264-021-01050-6

Related Literature

Article Analysis
・Side Effects of oxcarbazepine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.